STING1 and neoplasm: STING activation initiates a type I interferon (IFN)-driven pro-inflammatory program that stimulates basic leucine zipper transcriptional factor ATF-like 3 (BATF3)-dependent dendritic cell (DC) cross-presentation and promotes CD8+ T cell-mediated anti-tumor immune responses [279,280,281,282].